Zura Bio Ltd (ZURA) Stock Price, Quote & News

Company Profile

Zura Bio Limited, a clinical-stage biotechnology company, develops medicines for immune and inflammatory disorders in the United States. The company develops Tibulizumab, an immunoglobulin G-single-chain variable fragment bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes interleukin (IL)-17A and B-cell activating factor, which is in Phase 2 clinical trial development. It is also developing Torudokimab (ZB-880), a monoclonal antibody that ne...

Industry: Biotechnology

Sector: Healthcare

Phone: 702 825 9872

Website: zurabio.com

Address:

1489 W. Warm Springs Road, Suite 110, Henderson, United States

FilingTracker Jan. 27 at 10:23 PM

$ZURA 15.7% position of Athanor Capital revealed in 13D: https://www.sec.gov/Archives/edgar/data/1855644/000110465926007047/xslSCHEDULE_13D_X01/primary_doc.xml

0 · Reply

SMART4TRADER Jan. 22 at 6:45 PM

January 22, 2026 For potential momentum retention $NUAI $ZURA $IAUX

0 · Reply

hitmongreen Jan. 22 at 2:44 PM

$ZURA 🤔

0 · Reply

Shuqishuqi Jan. 22 at 11:31 AM

$ZURA man

0 · Reply

SadyK189 Jan. 22 at 4:56 AM

$ZURA Good. close of daily candle. Key support at 5.15 - 5.50. Next key level to test is 7.1 - 7.6. Currently at 6.40

0 · Reply

Smoothopera1or Jan. 22 at 2:11 AM

$ZURA 7-10$ possible?

0 · Reply

GSP Jan. 21 at 10:18 PM

Big breakout for $ZURA today. .

0 · Reply

GSP Jan. 21 at 10:13 PM

I cover the following stocks in my nightly video. $SPY $ZURA $MLTX $SLDB $ALT

1 · Reply

Yourboyy Jan. 21 at 9:38 PM

$ZURA brooooo

0 · Reply

L7_Trading Jan. 21 at 9:30 PM

Looks like they are going to Halt-Up YGHJ in to Close... YHGJ is breaking out now.. Are they pumping up ticker YHGJ for 400% today!? Its insane what's going on in this crazy market.. Looks like all eyes are going to YHGJ now.. $ATLN $IMTE $PRHI $ZURA wpc

0 · Reply

Zura Bio Appoints Immunology Industry Leader Sandeep Kulkarni, M.D. as Chief Executive Officer

Jan 12, 2026, 6:30 AM EST - 22 days ago

Zura Bio Reports Business Updates and Outlook for 2026

Nov 13, 2025, 6:30 AM EST - 2 months ago

Zura Bio Reports Third Quarter 2025 Financial Results and Recent Corporate Updates

Aug 20, 2025, 6:30 AM EDT - 5 months ago

Zura Bio to Participate in the Cantor Fitzgerald Global Healthcare Conference

Aug 14, 2025, 8:15 AM EDT - 6 months ago

Zura Bio Reports Second Quarter 2025 Financial Results and Recent Corporate Updates

Jul 17, 2025, 4:30 PM EDT - 7 months ago

Zura Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jul 1, 2025, 6:30 AM EDT - 7 months ago

Zura Bio Announces Chief Financial Officer Transition

May 27, 2025, 6:30 AM EDT - 9 months ago

Zura Bio to Present at the Jefferies Global Healthcare Conference

May 20, 2025, 6:30 AM EDT - 9 months ago

Zura Bio Launches Global Phase 2 TibuSHIELD Study to Evaluate Tibulizumab in Adults with Hidradenitis Suppurativa

May 8, 2025, 6:30 AM EDT - 9 months ago

Zura Bio Reports First Quarter 2025 Financial Results and Recent Corporate Updates

Mar 25, 2025, 6:30 AM EDT - 11 months ago

Zura Bio Reports Full Year 2024 Financial Results and Recent Corporate Updates

Feb 24, 2025, 6:30 AM EST - 1 year ago

Zura Bio to Present at the Leerink Partners Global Healthcare Conference

Dec 23, 2024, 6:30 AM EST - 1 year ago

Zura Bio Launches Global Phase 2 TibuSURE Study to Evaluate Tibulizumab in Adults With Systemic Sclerosis

Nov 25, 2024, 6:30 AM EST - 1 year ago

Zura Bio to Present at the Piper Sandler 36th Annual Healthcare Conference

Nov 14, 2024, 4:30 PM EST - 1 year ago

Zura Bio Announces Submission of Protocol to U.S. Food and Drug Administration for the Phase 2 Study of Tibulizumab in Adults with Systemic Sclerosis

Nov 7, 2024, 6:30 AM EST - 1 year ago

Zura Bio Reports Third Quarter 2024 Financial Results and Recent Corporate Updates

Oct 30, 2024, 6:30 AM EDT - 1 year ago

Zura Bio to Participate in Two Upcoming Investor Conferences in November

Sep 3, 2024, 6:00 AM EDT - 1 year ago

CPS HR Consulting Partners with GovInvest to Revolutionize Compensation Consulting with Advanced Technology

OGI

Sep 3, 2024, 6:00 AM EDT - 1 year ago

Zura Bio to Present at Three Upcoming Investor Conferences in September

Aug 13, 2024, 9:21 AM EDT - 1 year ago

Zura Bio Reports Second Quarter 2024 Financial Results and Recent Business Highlights

Aug 12, 2024, 4:05 PM EDT - 1 year ago

Zura Bio Completes Exchange Offer and Consent Solicitation and Notice to Exercise Right to Exchange Remaining Outstanding Warrants

Aug 9, 2024, 4:05 PM EDT - 1 year ago

Zura Bio Announces Expiration and Results of Exchange Offer and Consent Solicitation Relating to its Warrants

Jul 12, 2024, 6:10 AM EDT - 1 year ago

Zura Bio Commences Warrant Exchange Offer and Consent Solicitation

Jun 14, 2024, 6:00 AM EDT - 1 year ago

Zura Bio Presents Data for the Tibulizumab (ZB-106) Program at EULAR 2024

Jun 6, 2024, 6:00 AM EDT - 1 year ago

Zura Bio Forms Scientific Advisory Board with Prominent Specialists in Rheumatology, Dermatology, and Immunology

Jun 3, 2024, 6:00 AM EDT - 1 year ago

Zura Bio to Present Data Exploring the Expanded Potential of Tibulizumab (ZB-106) into Sjogren's Syndrome and Rheumatoid Arthritis at EULAR 2024

May 29, 2024, 6:00 AM EDT - 1 year ago

Zura Bio Announces Participation in June Investor Conferences

May 9, 2024, 6:00 AM EDT - 1 year ago

Zura Bio Reports First Quarter 2024 Financial Results and Recent Business Highlights

Apr 18, 2024, 9:22 AM EDT - 1 year ago

Zura Bio Announces Oversubscribed $112.5 Million Private Placement

Apr 8, 2024, 6:00 AM EDT - 1 year ago

Zura Bio Announces Robert Lisicki as CEO and Director

Mar 28, 2024, 6:00 AM EDT - 2 years ago

Zura Bio Reports Full Year 2023 Financial Results, Business Highlights, and Appoints Robert Lisicki as Chief Executive Officer

Mar 4, 2024, 6:00 AM EST - 2 years ago

Zura Bio Announces Participation at March Conferences

Feb 2, 2024, 6:00 AM EST - 2 years ago

Zura Bio Announces Participation at February Investor Conferences

Jan 8, 2024, 6:00 AM EST - 2 years ago

Zura Bio Continues to Strengthen Leadership with Appointment of Robert Lisicki as President and Kiran Nistala as CMO

Jan 3, 2024, 6:00 AM EST - 2 years ago

Zura Bio to Present at the 42nd Annual J.P. Morgan Healthcare Conference and Dermatology Summit

Dec 4, 2023, 6:00 AM EST - 2 years ago

Zura Bio Announces Two Immunology Abstracts Presented at the World Allergy Congress in Bangkok

Nov 14, 2023, 6:00 AM EST - 2 years ago

Zura Bio Appoints Arnout Ploos van Amstel to its Board of Directors

Nov 13, 2023, 6:30 AM EST - 2 years ago

Zura Bio Reports Third Quarter 2023 Financial Results and Recent Business Highlights

Sep 12, 2023, 5:00 AM EDT - 2 years ago

Zura Bio Enters into Sponsored Research Agreement with Benaroya Research Institute

Aug 14, 2023, 7:00 AM EDT - 2 years ago

Zura Bio Reports Second Quarter 2023 Financial Results and Recent Business Highlights

Jun 23, 2023, 6:30 AM EDT - 2 years ago

Zura Bio to Join the Russell 2000® and Russell 3000® Indexes

Jun 6, 2023, 4:00 AM EDT - 2 years ago

Zura Bio Completes Approximately $80 Million Financing with the Focus on Advancing ZB-106, a Potential First-in-class Anti-IL-17 and Anti-BAFF Dual Antagonist

Apr 27, 2023, 7:39 AM EDT - 3 years ago

Zura Bio Announces $80 Million Financing and the Licensing of Tibulizumab (ZB-106), a Potential First-in-Class anti-IL-17 and anti-BAFF Dual Antagonist for Autoimmune Diseases

Apr 14, 2023, 5:00 AM EDT - 3 years ago

Zura Bio Announces Appointment of Chief Scientific Officer

Mar 21, 2023, 6:13 AM EDT - 3 years ago

Zura Bio Limited Announces Closing of Business Combination with JATT Acquisition Corp

Mar 16, 2023, 4:17 PM EDT - 3 years ago

JATT Acquisition Corp Shareholders Approve Proposed Business Combination with Zura Bio Limited

FilingTracker Jan. 27 at 10:23 PM

$ZURA 15.7% position of Athanor Capital revealed in 13D: https://www.sec.gov/Archives/edgar/data/1855644/000110465926007047/xslSCHEDULE_13D_X01/primary_doc.xml

0 · Reply

SMART4TRADER Jan. 22 at 6:45 PM

January 22, 2026 For potential momentum retention $NUAI $ZURA $IAUX

0 · Reply

hitmongreen Jan. 22 at 2:44 PM

$ZURA 🤔

0 · Reply

Shuqishuqi Jan. 22 at 11:31 AM

$ZURA man

0 · Reply

SadyK189 Jan. 22 at 4:56 AM

$ZURA Good. close of daily candle. Key support at 5.15 - 5.50. Next key level to test is 7.1 - 7.6. Currently at 6.40

0 · Reply

Smoothopera1or Jan. 22 at 2:11 AM

$ZURA 7-10$ possible?

0 · Reply

GSP Jan. 21 at 10:18 PM

Big breakout for $ZURA today. .

0 · Reply

GSP Jan. 21 at 10:13 PM

I cover the following stocks in my nightly video. $SPY $ZURA $MLTX $SLDB $ALT

1 · Reply

Yourboyy Jan. 21 at 9:38 PM

$ZURA brooooo

0 · Reply

L7_Trading Jan. 21 at 9:30 PM

0 · Reply

RunnerSignals Jan. 21 at 9:29 PM

Market Warriors on the Rise! $ZURA $VIR $NFE $IBRX $AIRS started down but blasted back to close strong!

0 · Reply

BenKaitz Jan. 21 at 8:46 PM

$ZURA up 500% with a 1.01 average.

1 · Reply

stocktrade77 Jan. 21 at 8:40 PM

$PLRZ looking good, for a swing to 20s $PAVM $ADTX $CUE $ZURA

0 · Reply

BioTuesdays Jan. 21 at 7:25 PM

$ZURA has appointed Sandeep Kulkarni, MD, as chief executive officer (CEO), effective today https://biotuesdays.com/2026/01/21/zura-names-dr-sandeep-kulkarni-as-ceo/

0 · Reply

GSP Jan. 21 at 7:00 PM

$ZURA is trying to break out today. .

0 · Reply

topstockalerts Jan. 21 at 5:07 PM

Zura Bio Ltd announced the appointment of Sandeep Kulkarni, M.D., as Chief Executive Officer, effective January 21, 2026. He succeeds interim CEO Kim Davis, J.D., who had served in the role since October 2025 following a medical leave by former CEO Robert Lisicki, who has now stepped down from both management and the board. Dr. Kulkarni brings more than 20 years of experience across biotechnology, investment, entrepreneurship, and medicine. Most recently, he co-founded and served as CEO of Tourmaline Bio until its acquisition by Novartis, completed in October 2025. A Zura board member since its Nasdaq listing in March 2023, he has been involved with the company since its inception. Zura Bio is developing tibulizumab, described as the first and only bispecific antibody targeting both IL-17 and BAFF pathways for autoimmune diseases, with the company expecting two potentially transformative data readouts over the next 18 months. $ZURA

0 · Reply

Arcides Jan. 15 at 6:02 PM

$ZURA what a piece of shit today.

2 · Reply

dogDazeSummer Jan. 13 at 6:08 PM

$MLTX cheapest most de risked stock in entire $XBI index. Unlike others - the Moonlake approval will occur under same FDA administration Given new guidance just announced at JPM by FDA, this also creates tailwinds for $IFRX $ZURA PG/ HS. https://x.com/drmakaryfda/status/2010906917682757979?s=46&t=XjkRDPkufei_lYFEsHu0fA Importantly, Moonlake is now a slam dunk with data from P3 high placebo removed. Easy trade to $25

0 · Reply

DARKP00L Jan. 12 at 11:36 AM

$ZURA 06:33 on Jan. 12 2026 Zura Bio Targets Key 2026–2027 Trial Readouts as Lead Autoimmune Drug Advances, Eyes Transformational Data in 2026 as Tibulizumab Studies Progress #tradeideas

0 · Reply

octavia8 Jan. 7 at 3:55 PM

$ZURA why is this up??

1 · Reply

Trizzie0805 Jan. 2 at 3:20 PM

$ZURA $RIVN The work is working! $INVE is starting to move. $SG $RDW up next!! Remember set your mental stop to protect losses!!

0 · Reply

JoeMoney3 Jan. 2 at 1:26 PM

$BBAI Today Watch: $SOPA $ZURA $DVLT lets get it $$$💪

0 · Reply

Market Cap	369.33M
Revenue (ttm)	0.00
Net Income (ttm)	-45.39M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	511,000
Avg Vol	663,224
Day's Range	N/A - N/A
Shares Out	65.02M
Stochastic %K	73%
Beta	0.20
Analysts	Strong Sell
Price Target	$16.00